B cell receptor signaling in chronic lymphocytic leukemia.
Jan A. Burger,Nicholas Chiorazzi +1 more
Reads0
Chats0
TLDR
The evolution of this field is discussed, from BCR-related prognostic markers, to mechanisms of BCR activation, and targeting of B CR-associated kinases, the emerging Achilles' heel in CLL pathogenesis.About:
This article is published in Trends in Immunology.The article was published on 2013-12-01 and is currently open access. It has received 378 citations till now. The article focuses on the topics: B-cell receptor & Chronic lymphocytic leukemia.read more
Citations
More filters
Journal ArticleDOI
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
TL;DR: A large number of patients diagnosed with chronic lymphocytic leukemia have a history of atypical clinical course, suggesting that the disease typically occurs in elderly patients and has a highly variable clinical course.
Journal ArticleDOI
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
TL;DR: Chronic lymphocytic leukemia is the commonest leukemia in western countries and typically occurs in elderly patients and has a highly variable clinical course.
Journal ArticleDOI
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Jan A. Burger,Adrian Wiestner +1 more
TL;DR: B cells and B CR-related kinases also play a role in the microenvironment of solid tumours, such as squamous cell carcinoma and pancreatic cancer, and therefore targeting B cells or BCR- related kinases may have anticancer activity beyond B cell malignancies.
Journal ArticleDOI
The molecular pathogenesis of chronic lymphocytic leukaemia
TL;DR: This Review focuses on recent insights into the understanding of CLL biology, with emphasis on the role of genetic lesions in the initiation and clinical progression of Cll.
Journal ArticleDOI
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger,Dan A. Landau,Amaro Taylor-Weiner,Ivana Bozic,Huidan Zhang,Huidan Zhang,Huidan Zhang,Kristopher A. Sarosiek,Lili Wang,Chip Stewart,Jean Fan,Julia Hoellenriegel,Mariela Sivina,Adrian M. Dubuc,Cameron Fraser,Yu Long Han,Shuqiang Li,Kenneth J. Livak,Lihua Zou,Youzhong Wan,Sergej Konoplev,Carrie Sougnez,Jennifer R. Brown,Lynne V. Abruzzo,Scott L. Carter,Michael J. Keating,Matthew S. Davids,William G. Wierda,Kristian Cibulskis,Thorsten Zenz,Lillian Werner,Paola Dal Cin,Peter Kharchencko,Donna Neuberg,Hagop M. Kantarjian,Eric S. Lander,Stacey Gabriel,Susan O'Brien,Anthony Letai,David A. Weitz,Martin A. Nowak,Gad Getz,Catherine J. Wu,Catherine J. Wu,Catherine J. Wu +44 more
TL;DR: It is demonstrated that the ibrutinib therapy favours selection and expansion of rare subclones already present before ibrUTinib treatment, and insight is provided into the heterogeneity of genetic changes associated with ibrutsinib resistance.
References
More filters
Journal ArticleDOI
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
Michael E. Weinblatt,Arthur Kavanaugh,Mark C. Genovese,Theresa K. Musser,Elliott B. Grossbard,Daniel B. Magilavy +5 more
TL;DR: R788, an oral inhibitor of Syk, was significantly superior to placebo at month 6 and reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia.
Journal ArticleDOI
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Mary Ellen Conley,A. Kerry Dobbs,Dana Farmer,Sebnem Kilic,Kenneth Paris,Sofia Grigoriadou,Elaine Coustan-Smith,Vanessa Howard,Dario Campana +8 more
TL;DR: Identifying the genetic and environmental factors that influence the clinical phenotype may enhance patient care and the understanding of normal B cell development.
Journal ArticleDOI
The B-cell receptor signaling pathway as a therapeutic target in CLL
TL;DR: A summary of BCR signaling, tools for studying this pathway relevant to drug development in CLL, and early progress made with therapeutics targeting BCR-related kinases are provided.
Journal ArticleDOI
Targeting pathological B cell receptor signalling in lymphoid malignancies
Ryan M. Young,Louis M. Staudt +1 more
TL;DR: This work has shown that a host of therapeutic agents targeting effectors of the BCR signalling pathway are now in clinical trials and have shown initial success against multiple forms of lymphoma.
Journal ArticleDOI
Treatment of Rheumatoid Arthritis With a Syk Kinase Inhibitor A Twelve-Week, Randomized, Placebo-Controlled Trial
Michael E. Weinblatt,Arthur Kavanaugh,Ruben Burgos-Vargas,Ara Dikranian,Gabriel Medrano-Ramírez,J. Morales-Torres,Frederick T. Murphy,Theresa K. Musser,Nicholas Straniero,Angela V. Vicente-Gonzales,Elliott B. Grossbard +10 more
TL;DR: It is indicated that an inhibitor of Syk kinase produces significant clinical benefits at 12 weeks in a population of patients with active RA receiving methotrexate therapy, suggesting Syk Kinase may be an important new therapeutic target in RA and related autoimmune conditions.
Related Papers (5)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more